+

WO2003006036A2 - Preparation a base de plantes - Google Patents

Preparation a base de plantes Download PDF

Info

Publication number
WO2003006036A2
WO2003006036A2 PCT/IB2002/002698 IB0202698W WO03006036A2 WO 2003006036 A2 WO2003006036 A2 WO 2003006036A2 IB 0202698 W IB0202698 W IB 0202698W WO 03006036 A2 WO03006036 A2 WO 03006036A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical
medicinal preparation
herbs
cancer
treatment
Prior art date
Application number
PCT/IB2002/002698
Other languages
English (en)
Other versions
WO2003006036A3 (fr
Inventor
Ranjitsinh Solanki
Original Assignee
Sahajanand Biotech Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sahajanand Biotech Private Limited filed Critical Sahajanand Biotech Private Limited
Priority to US10/257,083 priority Critical patent/US6780441B2/en
Publication of WO2003006036A2 publication Critical patent/WO2003006036A2/fr
Publication of WO2003006036A3 publication Critical patent/WO2003006036A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A61K36/8905—Cyperus (flatsedge)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to a new herbal formulation which has been found to be effective for the treatment of cancer. More particularly, the formulation can be used to treat squamous cell carcinomas, tumours and other metastatic states, including lung cancer.
  • the conventional treatment of tumerous cancers comprises surgery, chemotherapy and/or radiotherapy.
  • the drugs given during chemotherapy are of necessity very powerful and, in consequence, can have serious and undesirable side-effects.
  • a pharmaceutical or medicinal preparation which comprises a mixture of the following eleven herbs: Withania somnifera, Chlorphyton borivilianum, Boerhavia diffusa, Elephantopus scaber, Moringa oleifera, Tecoma undulata, Bauhinia purpurea, Ficus racemosa, Cyperus rotundus, Sphaeranthus acmella and Tinospora cordifolia or a mixture of the active ingredients that have been extracted from those herbs or chemically synthesized.
  • This product has been found by the inventor to be particularly effective for the treatment of lung cancer, including all types of bronchogenic carcinomas and pleural malignancies.
  • the preparation is preferably formulated for administration to patients as a liquid or syrup, but could also be administered as a capsule or tablet.
  • the product of the present invention contains a mixture of herbs, or extracts from herbs, rather than being based on a single herb.
  • a synergistic effect has been noticed between the various ingredients.
  • the herbs when exhibited unexpected synergistic property.
  • the activities of similar herbs are combined to optimize and enhance the pharmacological effects without increasing the adverse toxic reactions (which becomes a distinct possibility if the herbs are used singly in a concentration of 100%).
  • the advantage of a multi-drug regimen also lies in the fact that the possibility of development of drug resistance is minimized.
  • MRI ii) improvement in the relevant biochemical parameters; and iii) disappearance of malignant cells from sputum and pleural fluid; and more subjectively: i) sense of well being, ii) improvement in appetite, and iii) increased vigour and enthusiasm in daily activities.
  • the formulation of this invention is itself effective for the treatment of cancer. It may also be used as an adjuvant to conventional modes of anticancer therapy, namely radiotherapy and/or chemotherapy.
  • the formulation may be presented as a dietary supplement for patients diagnosed as having any type of cancer. It may also be used to create a sense of general well being and to increase the vitality in patients diagnosed as having any type of cancer, to increase the appetite, restore health and increase the lifespan of patients diagnosed as having any type of cancer; to improve the ambulatory capacity in patients diagnosed as having any type of cancer; to activate the nervous system, prevent degenerative changes, stimulate regeneration and improve the psychological status in patients diagnosed as having any type of cancer, and to stimulate metabolism, accelerate anabolism, promote catabolism thereby flushing the body of toxic metabolites and reducing the side effects of chemotherapy and radiotherapy.
  • the hepatic clearance of substances like iron and ferritin in cases of thalassemia is also improved, thereby reducing the iron overload in such cases.
  • the extraction can be performed by using volatile freon gas.
  • This process has the advantage of being fast and also has the ability to preserve the active chemicals (alkaloids, non-alkaloids, electrolytes, minerals, etc.) in their natural form (as it does not involve heating and denaturation at any stage of the process).
  • Freon being a highly volatile compound with its boiling point at -21°C, evaporates totally after extraction, yielding an ultrapure concentrate of the chemicals.
  • the chemicals are thereafter diluted appropriately and mixed in the proportions mentioned in Table 1.
  • a male patient 42 years old and a habitual smoker was diagnosed as a stage III squamous cell carcinoma of lung with hepatic metastasis.
  • Two gelatin capsules containing 450 mg to 480 mg each of the powdered herbal formulation was administered to the patient once every 8 hours, three times a day.
  • the tumour size after six months of herbal therapy was the same as at the time of diagnosis.
  • the herbal formulation of the present invention has a very beneficial effect on apparently terminally ill patients suffering from malignant tumours and even metastatic carcinomas.
  • therapy with this formulation appears to have the advantages of targeting only malignant cells, producing no serious adverse side effects, causing no damage to healthy cells, improving the immuno-modulatory effect and also producing an anti-oxidant effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une préparation pharmaceutique ou médicinale comprenant un mélange composé des onze herbes suivantes: Withania somnifera, Chlorphyton borivilianum, Boerhavia diffusa, Elephantopus scaber, Moringa oleifera, Tecoma undulata, Bauhinia purpurea, Ficus racemosa, Cyperus rotundus, Sphaeranthus acmella et Tinospora cordifolia; ou un mélange des principes actifs extraits de ces herbes ou obtenus par synthèse chimique. La préparation à base de plantes décrite dans cette invention convient au traitement de cancers, en particulier, au traitement des carcinomes squameux, des tumeurs et autres états métastatiques parmi lesquels le cancer du poumon.
PCT/IB2002/002698 2001-07-11 2002-07-10 Preparation a base de plantes WO2003006036A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/257,083 US6780441B2 (en) 2001-07-11 2002-07-10 Composition of eleven herbals for treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116948.1A GB0116948D0 (en) 2001-07-11 2001-07-11 Herbal formulation
GB0116948.1 2001-07-11

Publications (2)

Publication Number Publication Date
WO2003006036A2 true WO2003006036A2 (fr) 2003-01-23
WO2003006036A3 WO2003006036A3 (fr) 2004-05-27

Family

ID=9918322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/002698 WO2003006036A2 (fr) 2001-07-11 2002-07-10 Preparation a base de plantes

Country Status (3)

Country Link
US (1) US6780441B2 (fr)
GB (2) GB0116948D0 (fr)
WO (1) WO2003006036A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016228A3 (fr) * 2004-08-02 2006-06-01 Kumar V Prashanth Alkaloide peptide cytotoxique et compositions pharmaceutiques pour le traitement des maladies neoplastiques
US7160561B2 (en) 2003-05-19 2007-01-09 Amazon Biotech Inc. Herbal composition and method of treating HIV infection
WO2007113646A3 (fr) * 2006-04-04 2008-07-03 Council Scient Ind Res Composition pharmaceutique utile en tant qu'agent immunomodulateur et procede pour sa preparation
CN103120727A (zh) * 2012-12-17 2013-05-29 广西梧州制药（集团）股份有限公司 一种治疗妇科炎症的中药组合物及其制备方法
US8541383B2 (en) 2007-11-22 2013-09-24 Laila Nutraceurticals Synergistic phytochemical composition for the treatment of obesity
CN106456687A (zh) * 2014-06-18 2017-02-22 韩国原子力研究院 包含辣木叶提取物的放射线联合处理用组合物及利用其的治疗方法
WO2018042229A1 (fr) * 2016-09-01 2018-03-08 Dias Dayanath Préparation pharmaceutique ou médicinale comprenant une combinaison de deux plantes médicinales emblica officinalis (nelli) et tinospora cordifolia (rasakinda) à administrer conjointement pour une stimulation ciblée du système immunitaire pour la prévention et le traitement du cancer de la cavité buccale
WO2020127072A1 (fr) * 2018-12-17 2020-06-25 Jucker Anca Gabriela Boisson fonctionnelle pour la santé

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070817B2 (en) * 2002-06-26 2006-07-04 Murali K Chada Herbal composition for treating or alleviating vascular headaches, neurological conditions and neurodegenerative diseases
GB0317020D0 (en) * 2003-07-21 2003-08-27 Sahajanand Biotech Private Ltd Herbo-mineral formulation for refractory leukemias and lymphomas
WO2006010069A1 (fr) * 2004-07-09 2006-01-26 Variety Children's Hospital D/B/A Miami Children's Hospital Materiaux et procedes pour une stimulation du systeme immunitaire
WO2006134609A2 (fr) * 2005-06-16 2006-12-21 Mmi Corporation Nouvel agent anticancereux, procedes de preparation et compositions pharmaceutiques correspondantes
WO2008020451A2 (fr) * 2006-08-14 2008-02-21 Nandan Biomatrix Limited Compositions nutraceutiques et procédés d'utilisation d'extraits de safed musli
TW200902504A (en) 2007-03-28 2009-01-16 Sumitomo Chemical Co Manufacturing method of trichloropyrimidine compound
US10391138B2 (en) * 2017-07-11 2019-08-27 Muniyal Ayurvedic Research Centre Multidimensional approach for Cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6746990A (en) * 1989-12-19 1991-07-18 Christian Kruger Use of parts of the natural plant tinospora
WO1994018993A1 (fr) * 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Composition therapeutique a base d'herbes
JPH07304685A (ja) * 1994-03-18 1995-11-21 Takeda Shokuhin Kogyo Kk 発癌プロモーション抑制組成物

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160561B2 (en) 2003-05-19 2007-01-09 Amazon Biotech Inc. Herbal composition and method of treating HIV infection
WO2006016228A3 (fr) * 2004-08-02 2006-06-01 Kumar V Prashanth Alkaloide peptide cytotoxique et compositions pharmaceutiques pour le traitement des maladies neoplastiques
WO2007113646A3 (fr) * 2006-04-04 2008-07-03 Council Scient Ind Res Composition pharmaceutique utile en tant qu'agent immunomodulateur et procede pour sa preparation
US8541383B2 (en) 2007-11-22 2013-09-24 Laila Nutraceurticals Synergistic phytochemical composition for the treatment of obesity
CN103120727A (zh) * 2012-12-17 2013-05-29 广西梧州制药（集团）股份有限公司 一种治疗妇科炎症的中药组合物及其制备方法
CN103120727B (zh) * 2012-12-17 2014-08-06 广西梧州制药（集团）股份有限公司 一种治疗妇科炎症的中药组合物及其制备方法
CN106456687A (zh) * 2014-06-18 2017-02-22 韩国原子力研究院 包含辣木叶提取物的放射线联合处理用组合物及利用其的治疗方法
WO2018042229A1 (fr) * 2016-09-01 2018-03-08 Dias Dayanath Préparation pharmaceutique ou médicinale comprenant une combinaison de deux plantes médicinales emblica officinalis (nelli) et tinospora cordifolia (rasakinda) à administrer conjointement pour une stimulation ciblée du système immunitaire pour la prévention et le traitement du cancer de la cavité buccale
WO2020127072A1 (fr) * 2018-12-17 2020-06-25 Jucker Anca Gabriela Boisson fonctionnelle pour la santé

Also Published As

Publication number Publication date
GB0116948D0 (en) 2001-09-05
US6780441B2 (en) 2004-08-24
GB2380672B (en) 2003-09-17
GB0216106D0 (en) 2002-08-21
WO2003006036A3 (fr) 2004-05-27
GB2380672A (en) 2003-04-16
US20040009240A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
EP0977556B1 (fr) Composition d'herbes destinee au traitement du carcinome de la prostate
US6780441B2 (en) Composition of eleven herbals for treating cancer
KR20140033394A (ko) 암을 치료하기 위한 약초 조성물
US7344738B2 (en) Herbal composition for treatment of immunocompromised conditions
CN109010468A (zh) 基于古方托里消毒散的抗肿瘤中药组合物及其制备方法和应用
US6649185B2 (en) Herbal formulation
WO2024001141A1 (fr) Utilisation d'une prescription calmante pour l'estomac à base d'herba agastachis dans la préparation d'un médicament pour résister à helicobacter pylori
CN113813347A (zh) 复方紫杉醇抗肿瘤胶囊药片的制备方法及工艺
US20030147896A1 (en) Herbal fomulation
CN110339276B (zh) 一种治疗消化道肿瘤的扶正清解中药及其制备方法
US7390514B2 (en) Herbal composition for treatment and maintenance of hormone dependent conditions, osteoporosis, circulatory conditions, and for use as an immunostimulant
CN102755600A (zh) 一种抗乳腺癌转移复发中药复方及其制备方法和应用
GB2404586A (en) Herbo-mineral formation for the treatment of cancer
CN101485716B (zh) 一种治疗放射损伤药物及其制备方法
CN100406026C (zh) 一种治疗慢性胃炎、胃癌的药物及其制备方法
WO2003097076A1 (fr) Preparations d'herbes destinees a lutter contre l'adenocarcinome de la prostate
US7368134B2 (en) Herbal composition for treatment and maintenance of hormone dependent conditions and circulatory conditions, and immunostimulation
JP2958198B2 (ja) 鎮痛用医薬組成物
CN113995820A (zh) 一种治疗恶性肿瘤的中药药剂及其制备方法
CN112656843A (zh) 一种治疗颈源性肩背痛的中药组合物及其制备方法和应用
CN112022896A (zh) 一种抗肿瘤中药复方软胶囊制剂及其制备方法和应用
CN103272167B (zh) 一种治疗慢性腹泻的药物及其制备方法
WO2024127434A1 (fr) Formulation à base de plusieurs plantes pour une action immunomodulatrice
CN108159232B (zh) 一种降低结直肠癌术后复发转移的中药制剂及其制备方法和应用
CN114306564A (zh) 用于治疗放化疗后骨髓抑制的中药组合物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10257083

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载